University of California Los Angeles-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014362)
◆英語タイトル:University of California Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014362
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:101
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
University of California Los Angeles (UCLA) a subsidiary of University of California is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, graduate degree and undergraduate degree program and also provides research services in libraries, museums, film, music archives, art galleries, horizon-broadening, humanity-serving of California. UCLA operates through its departments including anthropology, archaeology, applied linguistics, architecture and urban design, bio-engineering, bio-medical research, dentistry and digital humanities. The university also conducts variety of programs for students in community operations. UCLA is headquartered in Los Angeles, California, the US.

University of California Los Angeles – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California Los Angeles, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of California Los Angeles, Medical Devices Deals, 2011 to YTD 2017 10
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
University of California Los Angeles, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 13
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 14
Trethera Enters into Research Agreement with University of California, Los Angeles 16
Bristol-Myers Squibb Enters into Research Agreement with UCLA 17
BioNano Genomics Enters into Research Agreement with University of California, Los Angeles 18
Zymeworks Enters into Research Agreement with University of California, Los Angeles 19
NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 20
F. Hoffmann-La Roche Enters Into Co-Development Agreement With UCLA’s Jonsson Comprehensive 21
UCLA Medical Center Forms Joint Venture With First Affiliated Hospital Of Medical School 22
Licensing Agreements 23
Diamyd Medical Enters into Licensing Agreement with University of California 23
Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 24
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 25
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 26
Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 27
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 28
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 29
Fibrocell Science Enters Into Licensing Agreement With University of California 30
Asset Transactions 31
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 31
University of California Los Angeles – Key Competitors 33
University of California Los Angeles – Key Employees 34
University of California Los Angeles – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Joint Venture 37
Recent Developments 38
Government and Public Interest 38
Oct 12, 2017: NIH awards almost $10 million to UCLA Center for Autism Research and Treatment 38
Oct 09, 2017: Combination treatment targeting glucose in advanced brain cancer shows promising results in preclinical study 39
Sep 19, 2017: National Science Foundation awards $800K to researchers using MyLymeData 40
Sep 18, 2017: Behavioral therapy increases connectivity in brains of people with OCD 41
Sep 11, 2017: UCLA Launches CIRM-Funded Cancer Clinical Trial 42
Sep 07, 2017: NIH awards nearly $100 million for Autism Centers of Excellence program 43
Sep 06, 2017: UCLA receives $8.4 million NIH grant to help liver transplant recipients stay healthier longer 45
Aug 14, 2017: UCLA scientists identify a new way to activate stem cells to make hair grow 46
Aug 09, 2017: Stem cell center trainee receives grant to develop nanotechnologies to treat pediatric cancer 48
Jul 26, 2017: UCLA researchers reveal unusual chemistry of protein with role in neurodegenerative disorders 49
Jul 19, 2017: Less Invasive Treatment for Blocked Artery in the Leg is Safe, Review Finds 50
Jul 12, 2017: Electrical stimulation of brain may help people with schizophrenia learn to communicate better 51
Apr 05, 2017: UCLA researchers discover a new cause of high plasma triglycerides 52
Apr 03, 2017: Artificial thymus developed at UCLA can produce cancer-fighting T cells from blood stem cells 53
Mar 09, 2017: Targeting cancer stem cells improves treatment effectiveness and prevents metastasis 54
Feb 27, 2017: Guidelines for treating brain metastases should be overhauled, UCLA study finds 55
Feb 07, 2017: UCLA researchers turn stem cells into somites, precursors to skeletal muscle, cartilage and bone 56
Jan 30, 2017: UCLA will lead $21 million, grant-funded study of epilepsy after traumatic brain injuries 57
Jan 24, 2017: Combination therapy for glioblastoma shows promising results in early-stage research 58
Jan 12, 2017: With $3.2M grant, UCLA researcher to study cancer patients’ response to immunotherapy 59
Jan 10, 2017: Autism biomarker seen as boon for new treatments 60
Dec 22, 2016: With $8.6 million grant from NIH, UCLA-led consortium will map the heart’s nervous system 61
Dec 22, 2016: Protein that activates immune response harms body’s ability to fight HIV 62
Dec 13, 2016: Experimental implant shows promise for restoring voluntary movement after spinal cord injury 63
Oct 26, 2016: Study Questions Benefits of Long-Term Home Oxygen Therapy for COPD Patients with Moderately Low Blood Oxygen Levels 65
Sep 16, 2016: The Cancer Foundation supports a research project on radiotherapy involving LIH 67
Sep 15, 2016: UCLA researchers use stem cells to grow 3-D lung-in-a-dish 68
Sep 01, 2016: New TSRI Method Makes Building ‘One-Handed’ Drugs Easier than Ever 69
Aug 25, 2016: UCLA-led Study Sheds New Light on the Complex Genetics of Autism 71
Jul 22, 2016: UCLA Duchenne muscular dystrophy research receives grant from California’s stem cell agency 73
Jul 21, 2016: Three-drug combinations could help counter antibiotic resistance, UCLA biologists report 74
Jul 14, 2016: Cancer-fighting gene immunotherapy shows promise as treatment for HIV 76
Jun 20, 2016: Nonprofit co-founded by UCLA to form national institute to improve efficiency in manufacturing 77
May 31, 2016: UCLA researchers identify protein that could prevent tumor growth in cervical cancer 79
May 02, 2016: TGen SU2C Melanoma Dream Team Member Receives $200,000 Sharp Award 80
Apr 22, 2016: Widely used class of chemotherapy drugs does not lead to cognitive decline for women with breast cancer 83
Apr 13, 2016: Experimental therapy for brain cancer developed by UCLA and Caltech could prevent drug resistance 84
Apr 04, 2016: To treat a leading cause of osteoporosis, surgery is better than widely used medications 86
Mar 30, 2016: Spinal cord regeneration might actually be helped by glial scar tissue, contrary to conventional wisdom 87
Mar 28, 2016: New drug combinations could significantly improve tuberculosis treatment 89
Mar 22, 2016: UCLA stem cell researcher receives $7.6 million grant 90
Feb 10, 2016: Remote telemonitoring does not reduce hospital readmissions for heart failure patients 91
Feb 04, 2016: Standard method for deriving stem cells may be better for use in regenerative medicine 92
Product News 93
Oct 03, 2017: New method to measure cell stiffness could lead to improved cancer treatments 93
Jun 07, 2016: NantWorks Announces Breakthrough Nano-Thermal Blade Technology to Treat Rare Diseases Through Single Cell Surgery Enabling Mitochondria Transfer into Mammalian Cells 94
May 01, 2017: Combination therapy could provide new treatment option for ovarian cancer 95
Apr 04, 2017: Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles 97
Apr 04, 2016: UCLA Technology Key to Assessing PTSD in Children and Adolescents, Improves Patient Care Across the Globe 98
Jan 24, 2017: New tuberculosis therapy could be more potent than current treatments 99
Appendix 101
Methodology 101
About GlobalData 101
Contact Us 101
Disclaimer 101

List of Tables
University of California Los Angeles, Pharmaceuticals & Healthcare, Key Facts 2
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California Los Angeles, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California Los Angeles, Deals By Therapy Area, 2011 to YTD 2017 9
University of California Los Angeles, Medical Devices Deals, 2011 to YTD 2017 10
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 13
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 14
Trethera Enters into Research Agreement with University of California, Los Angeles 16
Bristol-Myers Squibb Enters into Research Agreement with UCLA 17
BioNano Genomics Enters into Research Agreement with University of California, Los Angeles 18
Zymeworks Enters into Research Agreement with University of California, Los Angeles 19
NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 20
F. Hoffmann-La Roche Enters Into Co-Development Agreement With UCLA's Jonsson Comprehensive 21
UCLA Medical Center Forms Joint Venture With First Affiliated Hospital Of Medical School 22
Diamyd Medical Enters into Licensing Agreement with University of California 23
Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 24
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 25
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 26
Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 27
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 28
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 29
Fibrocell Science Enters Into Licensing Agreement With University of California 30
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 31
University of California Los Angeles, Key Competitors 33
University of California Los Angeles, Key Employees 34
University of California Los Angeles, Subsidiaries 35
University of California Los Angeles, Joint Venture 37

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ University of California Los Angeles-製薬・医療分野:企業M&A・提携分析(University of California Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆